Welcome to our dedicated page for Corvex news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Corvex stock.
Corvex, Inc. reports developments in AI cloud computing and GPU-accelerated infrastructure for artificial intelligence workloads. Company news has centered on secure compute clusters, high-throughput storage, managed Kubernetes architecture, confidential computing for data in use, and Secure Model Weights for protected AI inference on third-party GPU infrastructure.
Updates also cover customer deployments, long-term GPU infrastructure arrangements, earnings calls, operating and financial results, and capital-structure actions. Corvex became the public company operating under MOVE after the completed combination with Corvex Legacy Holdings and the name change from Movano Inc. in March 2026.
Corvex (MOVE) launched Corvex Secure Model Weights, a patent-pending solution available early on March 12, 2026, that keeps AI model weights encrypted until they are decrypted inside GPU trusted execution environments. The design uses NVIDIA Confidential Computing, Intel TDX, post-quantum Kyber-768 key exchange, and open-source Confidential Containers for auditable, owner-controlled key custody.
Corvex (NASDAQ:MOVE) announced completion and verification of a production deployment of confidential computing on NVIDIA HGX B200 systems on March 3, 2026. The deployment validates encrypted GPU-to-GPU communications across NVIDIA NVSwitch and NVLink and includes CPU and GPU remote attestation via Intel Trust Authority.
This establishes confidential computing as a production-ready infrastructure primitive for AI workloads, delivering near-native performance while providing runtime cryptographic proof of platform integrity to support regulated, multi-tenant, and sovereign AI deployments.
Corvex (NYSE:MOVE) announced completion and verification of a production deployment of confidential computing on NVIDIA HGX B200 systems on March 3, 2026. The deployment validates encrypted GPU-to-GPU communication across NVIDIA NVSwitch and NVLink using Intel Trust Domain Extensions and NVIDIA Confidential Computing, with CPU and GPU remote attestation via Intel Trust Authority.
This establishes confidential computing as an operational, production-ready infrastructure primitive for AI workloads, claiming near-native performance while protecting data and models in use to support regulated, multi-tenant, and sovereign AI deployments.
Corvex (NYSE:MOVE) announced a long-term lease to deploy a dedicated cluster of NVIDIA H200 GPUs for an AI-driven high-performance battery technologies provider on January 22, 2026. Corvex will supply hyperscaler-class, fully managed GPU infrastructure and a Kubernetes service designed to maximize compute density, reduce idle capacity, and allow burst scaling for peak training and inference workloads. The solution includes a secure on-premise option with hardware-enforced encryption, remote attestation, and payload-free telemetry to support sensitive model training, data-sovereignty, and enterprise compliance.
This deployment aims to enable the customer to expand into security-conscious enterprise markets while lowering infrastructure operating burden and cost relative to public hyperscalers.
Movano (NASDAQ: MOVE) and Corvex announced an all-stock merger effective Nov 10, 2025 that will bring Corvex public via combination into a pure-play AI infrastructure platform.
Key terms: merger exchange ratio tied to a $6.25 per Movano share, Corvex and Movano raised an aggregate $40.0 million in concurrent private placements, and Corvex shareholders will receive 46.6 million shares of Movano.
Movano Health will resume marketing its medical device operations including the FDA-cleared EvieMED Ring and proprietary mmWave RF technology.
Movano Health (NASDAQ: MOVE) will implement a 1-for-10 reverse stock split effective 12:01 a.m. Eastern on October 10, 2025. Shares are expected to trade on a split-adjusted basis when markets open on October 10, 2025, and the company will continue to trade under the symbol MOVE. The new CUSIP will be 62459M305. Outstanding shares will be reduced from approximately 8.3 million to approximately 0.8 million. The Reverse Stock Split is intended to increase the bid price to regain compliance with Nasdaq minimum bid price rules. Fractional shares will be paid in cash; equity awards will receive proportionate adjustments.
Movano Health (Nasdaq: MOVE) has received a listing extension from the Nasdaq Hearings Panel to maintain its listing status. The company must meet two key conditions: file its Q1 and Q2 2025 quarterly reports by September 30, 2025, and demonstrate compliance with the $1.00 minimum bid price requirement by October 30, 2025.
To address the bid price requirement, Movano has scheduled a shareholder meeting for September 26, 2025, where stockholders will vote on a proposed reverse stock split. The company is actively working with its new auditor to complete and file the delayed quarterly reports within the extension period.
Movano Health (Nasdaq: MOVE) has received a notice of non-compliance from Nasdaq due to failing to file its Q2 2025 Form 10-Q by the August 14, 2025 deadline. The company appealed its previous delisting determination at a Nasdaq Hearing Panel on August 19, 2025, presenting a compliance plan to address both the filing requirement and the $1.00 minimum bid price requirement.
As part of its compliance efforts, Movano Health engaged RBSM LLP as its new independent registered public accounting firm on August 13, 2025. The company is currently awaiting the Panel's determination, with no guarantee that it will be granted a trading suspension stay or maintain its Nasdaq listing.
Movano Health (NASDAQ: MOVE) received a delisting determination from The Nasdaq Capital Market on July 7, 2025, due to two compliance issues: failure to maintain the minimum $1.00 per share bid price requirement and late filing of its Form 10-Q for Q1 2025.
The company plans to request a hearing before a Nasdaq Hearings Panel and will seek an extended stay of the delisting process. Due to a reverse stock split within the past year, Movano is not eligible for the standard compliance period typically granted for bid price violations.
Movano Health (MOVE) has received a notification from Nasdaq regarding non-compliance with listing rules due to its failure to file the Form 10-Q for Q1 2025 on time. The quarterly report was due on May 15, 2025. The company has until July 21, 2025 to submit a compliance plan to Nasdaq. If the plan is accepted, Movano could receive up to 180 calendar days (until November 11, 2025) to file the delayed Form 10-Q. If Nasdaq rejects the plan, Movano will have the opportunity to appeal to a Nasdaq Hearings Panel.